Atrasentan

IUPAC: (2R, 3R, 4S ) -1 - [( dibutylcarbamoyl ) methyl] - 2 - (p-methoxyphenyl ) -4 - [ 3,4 - ( methylenedioxy) phenyl] - 3- pyrrolidincarboxylsäure

L01XX

Cytostatic

Template: Infobox chemical / molecular formula search available

Atrasentan ( ABT -627 ) is an experimental drug that is being developed for the treatment of prostate cancer and albuminuria in diabetic nephropathy.

The cytostatic effect of atrasentan comes about through its antagonistic binding to the endothelin -A receptor. Characterized it reduced cell proliferation, and metastasis of tumor cells. Atrasentan is in the United States as Xinlay ® (manufacturer: Abbott) prior to launch.